Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Arnica Extract→

Arnica Extract Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8057-65-6
Molecular formula
C197H188F19N41O28S6
Molecular weight
4131 g/mol
Drug class
Botanical topical preparationArnica montana extract, traditionally used as a counterirritant
Mechanism of action
The extract contains sesquiterpene lactones and other plant constituents with proposed local anti-inflammatory effects. The mechanism and clinical contribution of individual constituents are not fully established; topical use is associated with sensitisation risk.
Indications / reported uses
  • Traditional topical use for bruises, contusions and local muscle soreness in products authorised for external use; not for application to broken skin or mucous membranes unless the product label specifically permits

Sources: EMA/HMPC — Arnica montana herbal medicinal product information · NCCIH — Arnica · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Arnica Extract Environmental Risk Assessment (ERA) (the Arnica Extract ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.